BDT272
Pre-clinical- Indications
- Chronic pain, Neuropathic pain
Company intelligence / Profile preview
Biodol
Clapiers (HQ), Occitanie, Francebiodol.eu ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Biodol Therapeutics is developing first-in-class compounds for pain management, focusing on FLT3 receptor inhibition. Their compounds can be used as oral monotherapy for neuropathic pain and in combination with opioids to enhance analgesia while reducing opioid tolerance and hyperalgesia.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesNegative Allosteric Modulators (NAMs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
V-Bio VenturesBPI FranceInstitute for Neurosciences of MontpellierLaboratory for Therapeutic Innovation in Strasbourg
Beyond the preview
Go deeper on Biodol.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biodol.